1. AstraZeneca's COVID-19 vaccine 70% effective in trials, shares fall — Merck to acquire OncoImmune, accelerating development of COVID treatment candidate — Legend Biotech founder Frank Zhang arrested — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Wockhardt Ped contract

Discussion in 'Innovex' started by Anonymous, Feb 4, 2011 at 3:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Does anyone have any info on this contract? They are hiring in my area and I have an interview next week but haven't heard anything about pay, contract term, etc.
     

  2. Anonymous

    Anonymous Guest

    You have to Wock-Hard for these guys
     
  3. Anonymous

    Anonymous Guest

    Take this job ONLY if you have too. Right now there is no product and just lost Medicaid coverage. The managers are great but the Lead is a nightmare! Micromanagment at its worst.
     
  4. Anonymous

    Anonymous Guest

    I have an interview with them as well. Not sure about pay etc.. yet. I found it strange they are going in as Quintiles and not Innovex which is who I knew them as. Seems like they are looking for experienced reps that are non-pharma. I was told contract has been around for 3 yrs already which sounds like to me could end tomorrow for all we know. I assume it is salary of $50-$60 plus around $10-$15k bonus at plan.
     
  5. Anonymous

    Anonymous Guest

    Wocking hard is the name of the game here. No slack offs need apply. Was hired a year ago and never see my wife and kids. Spend 24/7 wocking hard on this contract. Please forgive my mispronounciation. Would you like a side of flied lice with that! Now back to wanking my wock.

    Won Hung Lo
     
  6. Anonymous

    Anonymous Guest

    don't even interview. you will never make bonus, you can not sell what they do not have and they do not have product. incompetent, unethical, dishonest sums up this company (both Wockhardt and Innovex). It's not just the lead that micro-manages either.
     
  7. Anonymous

    Anonymous Guest

    For the reps that have worked or are working for the Wockhardt contract, what is the salary, is there car allowance etc?
     
  8. Anonymous

    Anonymous Guest

    Isn't that pretty true of all contracts?
     
  9. Anonymous

    Anonymous Guest

    Fuck u
     
  10. Anonymous

    Anonymous Guest

    Wock hard, wock hard and then wock harder! You will make bonus! How bout a fortune nookie?
     
  11. Anonymous

    Anonymous Guest

    the starting salary is 55k no exceptions on experience. gas card and car allowance is $650./month.
     
  12. Anonymous

    Anonymous Guest

     
  13. Anonymous

    Anonymous Guest

    Wockhardt say that my wocker wasn't hardt enough and needed some additional wok. Went to lab for wock-up and all they said was . . . . . . woman who fly upside down have cwack up!

    What's wock with them??
     
  14. Anonymous

    Anonymous Guest

    Wockhardt sells lindane, why would you want to promote a toxin to be used on children?
     
  15. Anonymous

    Anonymous Guest

    It's a pretty good deal if you have Medicaid
    coverage. It's possible to work smart and have great
    quality of life. Don't expect to ever get promoted or
    Ever make close to six figures.
     
  16. Anonymous

    Anonymous Guest

    Same Wockhardt?

    Wockhardt Managing Director Murtaza Khorakiwala
    Indian generic manufacturer Wockhardt has begun to feel the sting of an FDA ban on drugs made at two of its plants, with fourth quarter profits falling 78%. And worse may still be to come, with the FDA issuing a Form 483 to the facility in Illinois that is the engineroom of Wockhardt's U.S. business.

    Livemint reports Wockhardt's fourth quarter U.S. sales are estimated to have fallen more than 50% year-on-year, with the FDA import alert against two Indian facilities accounting for the decline. As the import alerts mounted up last year, the one bright spot for Wockhardt was the continued quality compliance of the Illinois-based unit that generates more than half of U.S. sales. Now this too is under threat.

    The Form 483 could be resolved without significantly affecting Wockhardt's business, but fears of another import alert loom. Wockhardt has taken steps to stop the situation from escalating by responding to FDA's observations, but the final outcome is unpredictable. "It's difficult to say what kind of position the FDA will take but according to us the inspection was not a very negative inspection," Wockhardt's Managing Director Murtaza Khorakiwala told analysts at a briefing attended by Reuters.

    Khorakiwala was equally unsure about how FDA will respond to its attempts to fix the two plants in India that have been under import alerts since last year. While Khorakiwala thinks the facilities have made "significant progress," the only available independent assessment comes from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA). Khorakiwala said the MHRA saw signs of improvement at the Chikalthana site, but is yet to lift the restrictions it imposed in 2013.
     
  17. Anonymous

    Anonymous Guest

    The same. Same scummy company, same scummy contract.